Intravitreal bevacizumab administration for the treatment of chronic central serous chorioretinopathy

Wang, 2008, Central serous chorioretinopathy, Acta Ophthalmol, 86, 126, 10.1111/j.1600-0420.2007.00889.x Marmor, 1999, Central serous chorioretinopathy: bilateral multifocal electroretinographic abnormalities, Arch Ophthalmol, 117, 184, 10.1001/archopht.117.2.184 Spitznas, 1986, Pathogenesis of central serous retinopathy: a new working hypothesis, Graefes Arch Clin Exp Ophthalmol, 224, 321, 10.1007/BF02150023 Marmor, 1988, New hypotheses on the pathogenesis and treatment of serous retinal detachment, Graefes Arch Clin Exp Ophthalmol, 226, 548, 10.1007/BF02169203 Burumcek, 1997, Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up, Ophthalmology, 104, 616, 10.1016/S0161-6420(97)30262-0 Piccolino, 2003, Photodynamic therapy for chronic central serous chorioretinopathy, Retina, 23, 752, 10.1097/00006982-200312000-00002 Torres-Soriano, 2008, A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports), Graefes Arch Clin Exp Ophthalmol, 246, 1235, 10.1007/s00417-008-0856-x von Graefe, 1866, Central recurrent retinitis, Graefes Arch Clin Exp Ophthalmol, 12, 211 Schaal, 2009, Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy, Eur J Ophthalmol, 19, 613, 10.1177/112067210901900415 Venkatesh, 2018, Efficacy of oral rifampicin in chronic central serous chorioretinopathy, Ther Adv Ophthalmol, 10 Hanumunthadu, 2018, Management of chronic central serous chorioretinopathy, Indian J Ophthalmol, 66, 1704, 10.4103/ijo.IJO_1077_18 Doepfner, 2018, Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study, Clin Ophthalmol, 12, 1301, 10.2147/OPTH.S165199 Müller, 2018, Navigated laser photocoagulation in patients with non-resolving and chronic central serous chorioretinopathy, Graefes Arch Clin Exp Ophthalmol, 256, 1581, 10.1007/s00417-018-4031-8 Park, 2016, Effects of two different doses of intravitreal bevacizumab on subfoveal choroidal thickness and retinal vessel diameter in branch retinal vein occlusion, Int J Ophthalmol, 9, 999 Maryam, 2018, Short term effect of intravitreal bevacizumab for diabetic macular edema associated with epiretinal membrane, Rom J Ophthalmol, 62, 212, 10.22336/rjo.2018.32 Khan, 2017, High-dose (2.5 mg) intravitreal bevacizumab as rescue therapy for persistent postradiation cystoid macular edema, Ocul Oncol Pathol, 3, 168, 10.1159/000448719 Riazi-Esfahani, 2010, Ketoconazole in the treatment of central serous chorioretinopathy, Iran J Ophthalmol, 22, 59 Chan, 2003, Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level, Br J Ophthalmol, 87, 1453, 10.1136/bjo.87.12.1453 Nassisi, 2017, Short-Term choriocapillaris changes in patients with central serous chorioretinopathy after half-dose photodynamic therapy, Int J Mol Sci, 18, E2468, 10.3390/ijms18112468 Colucciello, 2006, Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy, Retina, 26, 239, 10.1097/00006982-200602000-00027 Lim, 2014, Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy, Ophthalmology, 121, 1073, 10.1016/j.ophtha.2013.11.040 Lee, 2009, Severe Choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy, Jpn J Ophthalmol, 53, 52, 10.1007/s10384-008-0613-z van Dijk, 2018, Short-Term findings on optical coherence tomography and Microperimetry in chronic central serous Chorioretinopathy patients treated with half-dose photodynamic therapy, Retin Cases Brief Rep, 12, 266, 10.1097/ICB.0000000000000498 2001, Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with Verteporfin. 1-year results of a randomized clinical trial–Vip report no. 1, Ophthalmology, 108, 841, 10.1016/S0161-6420(01)00544-9 Ober, 2007, Focal retinal pigment epithelium breaks in central serous chorioretinopathy, Retin Cases Brief Rep, 1, 271, 10.1097/01.iae.0000243067.71211.88 Ober, 2005, Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy, Ophthalmology, 112, 2088, 10.1016/j.ophtha.2005.06.026 Maruko, 2010, Subfoveal choroidal thickness after treatment of central serous chorioretinopathy, Ophthalmology, 117, 1792, 10.1016/j.ophtha.2010.01.023 Bae, 2011, A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy, Am J Ophthalmol, 152, 784, 10.1016/j.ajo.2011.04.008 Gass, 1967, Pathogenesis of disciform detachment of neuroepithelium, Am J Ophthalmol, 63, 1 Scheider, 1993, Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser ophthalmoscopy, Am J Ophthalmol, 115, 50, 10.1016/S0002-9394(14)73524-X Guyer, 1994, Digital indocyanine-green videoangiography of occult choroidal neovascularization, Ophthalmology, 101, 1727, 10.1016/S0161-6420(13)31433-X Imamura, 2009, Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy, Retina, 29, 1469, 10.1097/IAE.0b013e3181be0a83 Inoue, 2011, Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy, Ophthalmologica, 225, 37, 10.1159/000314709 Lim, 2010, Intravitreal bevacizumab injection for central serous chorioretinopathy, Retina, 30, 100, 10.1097/IAE.0b013e3181bcf0b4 Entezari, 2012, Intravitreal bevacizumab for treatment of refractory central serous choroidoretinopathy, Korean J Ophthalmol, 26, 139, 10.3341/kjo.2012.26.2.139 Chung, 2019, Twelve-month efficacy of intravitreal bevacizumab injection for chronic, atypical or recurrent central serous chorioretinopathy, Retina, 39, 134, 10.1097/IAE.0000000000001917 Ünlü, 2016, Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for central serous chorioretinopathy, Arq Bras Oftalmol, 79, 308, 10.5935/0004-2749.20160088 Semeraro, 2012, Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy, Jpn J Ophthalmol, 56, 608, 10.1007/s10384-012-0162-3 Maier, 2011, Therapy options for chronic central serous chorioretinopathy. Photodynamic therapy combined with bevacizumab - a case series, Ophthalmologe, 108, 1027, 10.1007/s00347-011-2419-5 Asahi, 2017, Photodynamic therapy combined with antivascular endothelial growth factor treatment for recalcitrant chronic central serous chorioretinopathy, Clin Ophthalmol, 11, 2051, 10.2147/OPTH.S135461 Arevalo, 2011, Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up, Graefes Arch Clin Exp Ophthalmol, 249, 1159, 10.1007/s00417-011-1651-7 Naseripour, 2016, Half-dose photodynamic therapy for chronic central serous chorioretinopathy, J Ophthalmic Vis Res, 11, 66, 10.4103/2008-322X.180706